Login Register Cart 0
Generic placeholder image

Current Nutrition & Food Science

Editor-in-Chief

ISSN (Print): 1573-4013
ISSN (Online): 2212-3881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Mechanisms behind the Role of SIBO in Non-Alcoholic Fatty Liver Disease: An Interplay between Liver, Gut Microbiota and Nutrition

Author(s): Aslı Yiğit* and Gülhan Samur

Volume 19, Issue 2, 2023

Published on: 05 August, 2022

Page: [84 - 93] Pages: 10

DOI: 10.2174/1573401318666220520100202

Price: $65

Abstract

Nonalcoholic fatty liver disease (NAFLD) is known as the leading cause of chronic liver disease in both children and adults. Increasing evidence suggests that dysbiosis of the intestinal microbiota plays a key role in the regulation of various metabolic and inflammatory pathways, which may result in the development of NAFLD. When normal liver physiology is impaired, gut-derived factors may lead to increased tissue damage and inflammation. Small intestinal bacterial overgrowth (SIBO) is defined as a condition in which a large amount of intestinal bacteria are present in the small intestine. The permeability of the intestinal barrier increases with SIBO, resulting in an increase in bacterial translocation and endotoxemia. SIBO is assumed to play a critical role in the development and progression of NAFLD. Therefore, this review focuses on the mechanisms in which SIBO may play a role in NAFLD and possible nutritional management strategies such as a low FODMAP diet, probiotics and prebiotics targeting SIBO and NAFLD.

Keywords: NAFLD, SIBO, gut microbiota, gut-liver axis, inflammation, nutrition.

« Previous
Graphical Abstract

[1]
Kolay E, Bykowska-Derda A, Abdulsamad S, et al. Self-reported eating speed is associated with indicators of obesity in adults: A systematic review and meta-analysis. Healthcare 2021; 9(11): 1559.
[http://dx.doi.org/10.3390/healthcare9111559] [PMID: 34828605]
[2]
Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism 2016; 65(8): 1017-25.
[http://dx.doi.org/10.1016/j.metabol.2016.01.012] [PMID: 26997539]
[3]
Talens M, Tumas N, Lazarus JV, Benach J, Pericàs JM. What do we know about inequalities in NAFLD distribution and outcomes? A scoping review. J Clin Med 2021; 10(21): 5019.
[http://dx.doi.org/10.3390/jcm10215019] [PMID: 34768539]
[4]
Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int 2017; 37 (Suppl. 1): 81-4.
[http://dx.doi.org/10.1111/liv.13299] [PMID: 28052624]
[5]
Scorletti E, West AL, Bhatia L, et al. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. J Hepatol 2015; 63(6): 1476-83.
[http://dx.doi.org/10.1016/j.jhep.2015.07.036] [PMID: 26272871]
[6]
Targher G, Byrne CD. Clinical review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98(2): 483-95.
[http://dx.doi.org/10.1210/jc.2012-3093] [PMID: 23293330]
[7]
Fitriakusumah Y, Lesmana CRA, Bastian WP, et al. The role of Small Intestinal Bacterial Overgrowth (SIBO) in Non-alcoholic Fatty Liver Disease (NAFLD) patients evaluated using Controlled Attenuation Parameter (CAP) Transient Elastography (TE): A tertiary referral center experience. BMC Gastroenterol 2019; 19(1): 43.
[http://dx.doi.org/10.1186/s12876-019-0960-x] [PMID: 30894137]
[8]
Machado MV, Cortez-Pinto H. Diet, microbiota, obesity, and NAFLD: A dangerous quartet. Int J Mol Sci 2016; 17(4): 481.
[http://dx.doi.org/10.3390/ijms17040481] [PMID: 27043550]
[9]
Tarantino G, Citro V, Capone D. Nonalcoholic fatty liver disease: A challenge from mechanisms to therapy. J Clin Med 2019; 9(1): 15.
[http://dx.doi.org/10.3390/jcm9010015] [PMID: 31861591]
[10]
Iino C, Endo T, Mikami K, et al. Significant decrease in Faecalibacterium among gut microbiota in nonalcoholic fatty liver disease: A large BMI- and sex-matched population study. Hepatol Int 2019; 13(6): 748-56.
[http://dx.doi.org/10.1007/s12072-019-09987-8] [PMID: 31515740]
[11]
Monga Kravetz A, Testerman T, Galuppo B, et al. Effect of gut microbiota and PNPLA3 rs738409 variant on Non-Alcoholic Fatty Liver Disease (NAFLD) in obese youth. J Clin Endocrinol Metab 2020; 105(10): e3575-85.
[http://dx.doi.org/10.1210/clinem/dgaa382] [PMID: 32561908]
[12]
Wijarnpreecha K, Lou S, Watthanasuntorn K, et al. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2020; 32(5): 601-8.
[http://dx.doi.org/10.1097/MEG.0000000000001541] [PMID: 31567712]
[13]
Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017; 14(1): 32-42.
[http://dx.doi.org/10.1038/nrgastro.2016.147] [PMID: 27729660]
[14]
Carr RM, Oranu A, Khungar V. Nonalcoholic fatty liver disease: Pathophysiology and management. Gastroenterol Clin North Am 2016; 45(4): 639-52.
[http://dx.doi.org/10.1016/j.gtc.2016.07.003] [PMID: 27837778]
[15]
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases. Hepatology 2018; 67(1): 328-57.
[http://dx.doi.org/10.1002/hep.29367] [PMID: 28714183]
[16]
Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24(7): 908-22.
[http://dx.doi.org/10.1038/s41591-018-0104-9] [PMID: 29967350]
[17]
Byrne CD, Targher G. NAFLD: A multisystem disease. J Hepatol 2015; 62(1) (Suppl.): S47-64.
[http://dx.doi.org/10.1016/j.jhep.2014.12.012] [PMID: 25920090]
[18]
Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism 2016; 65(8): 1038-48.
[http://dx.doi.org/10.1016/j.metabol.2015.12.012] [PMID: 26823198]
[19]
Augustyn M, Grys I, Kukla M. Small intestinal bacterial overgrowth and nonalcoholic fatty liver disease. Clin Exp Hepatol 2019; 5(1): 1-10.
[http://dx.doi.org/10.5114/ceh.2019.83151] [PMID: 30915401]
[20]
Kitade H, Chen G, Ni Y, Ota T. Nonalcoholic fatty liver disease and insulin resistance: New insights and potential new treatments. Nutrients 2017; 9(4): 387.
[http://dx.doi.org/10.3390/nu9040387] [PMID: 28420094]
[21]
Wieser V, Adolph TE, Enrich B, Moser P, Moschen AR, Tilg H. Weight loss induced by bariatric surgery restores adipose tissue PNPLA3 expression. Liver Int 2017; 37(2): 299-306.
[http://dx.doi.org/10.1111/liv.13222] [PMID: 27514759]
[22]
Martins IJ. Nutrition therapy regulates caffeine metabolism with relevance to NAFLD and induction of type 3 diabetes. J Diabetes Metab Disord 2017; 4(1): 1-9.
[23]
Martins IJ. Single gene inactivation with implications to diabetes and multiple organ dysfunction syndrome. J Clin Epigenet 2017; 3(3): 24.
[http://dx.doi.org/10.21767/2472-1158.100058]
[24]
Xu F, Gao Z, Zhang J, et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1+/- mice: A role of lipid mobilization and inflammation. Endocrinology 2010; 151(6): 2504-14.
[http://dx.doi.org/10.1210/en.2009-1013] [PMID: 20339025]
[25]
Ding RB, Bao J, Deng CX. Emerging roles of SIRT1 in fatty liver diseases. Int J Biol Sci 2017; 13(7): 852-67.
[http://dx.doi.org/10.7150/ijbs.19370] [PMID: 28808418]
[26]
Sharpton SR, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: From composition to function. Clin Gastroenterol Hepatol 2019; 17(2): 296-306.
[http://dx.doi.org/10.1016/j.cgh.2018.08.065] [PMID: 30196156]
[27]
Rojo D, Méndez-García C, Raczkowska BA, et al. Exploring the human microbiome from multiple perspectives: Factors altering its composition and function. FEMS Microbiol Rev 2017; 41(4): 453-78.
[http://dx.doi.org/10.1093/femsre/fuw046] [PMID: 28333226]
[28]
Nongthombam S, Nayak B, Kumar A, Roy N, Sachdev V, Acharya S. Prevalence of Small Intestinal Bacterial Overgrowth (SIBO) and insulin resistance in both obese and non-obese Non-Alcoholic Fatty Liver Disease (NAFLD) patients. J Clin Exp Hepatol 2015; 5: S23-4.
[http://dx.doi.org/10.1016/j.jceh.2015.07.265]
[29]
Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 2010; 5(2): e9085.
[http://dx.doi.org/10.1371/journal.pone.0009085] [PMID: 20140211]
[30]
Le Roy T, Llopis M, Lepage P, et al. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut 2013; 62(12): 1787-94.
[http://dx.doi.org/10.1136/gutjnl-2012-303816] [PMID: 23197411]
[31]
Aron-Wisnewsky J, Vigliotti C, Witjes J, et al. Gut microbiota and human NAFLD: Disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020; 17(5): 279-97.
[http://dx.doi.org/10.1038/s41575-020-0269-9] [PMID: 32152478]
[32]
Dumas ME, Barton RH, Toye A, et al. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci USA 2006; 103(33): 12511-6.
[http://dx.doi.org/10.1073/pnas.0601056103] [PMID: 16895997]
[33]
Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol 2018; 15(2): 111-28.
[http://dx.doi.org/10.1038/nrgastro.2017.119] [PMID: 29018272]
[34]
Jiang C, Xie C, Li F, et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest 2015; 125(1): 386-402.
[http://dx.doi.org/10.1172/JCI76738] [PMID: 25500885]
[35]
Freeland KR, Wilson C, Wolever TM. Adaptation of colonic fermentation and glucagon-like peptide-1 secretion with increased wheat fibre intake for 1 year in hyperinsulinaemic human subjects. Br J Nutr 2010; 103(1): 82-90.
[http://dx.doi.org/10.1017/S0007114509991462] [PMID: 19664300]
[36]
Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(17): 2019-28.
[http://dx.doi.org/10.3748/wjg.v25.i17.2019] [PMID: 31114130]
[37]
Shah M, Vella A. Effects of GLP-1 on appetite and weight. Rev Endocr Metab Disord 2014; 15(3): 181-7.
[http://dx.doi.org/10.1007/s11154-014-9289-5] [PMID: 24811133]
[38]
Zhang JM, Sun YS, Zhao LQ, et al. SCFAs-induced GLP-1 secretion links the regulation of gut microbiome on hepatic lipogenesis in chickens. Front Microbiol 2019; 10: 2176.
[http://dx.doi.org/10.3389/fmicb.2019.02176] [PMID: 31616396]
[39]
Son G, Kremer M, Hines IN. Contribution of gut bacteria to liver pathobiology Gastroenterol Res and Pract 2010; 2010.
[http://dx.doi.org/10.1155/2010/453563]
[40]
Compare D, Coccoli P, Rocco A, et al. Gut liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2012; 22(6): 471-6.
[http://dx.doi.org/10.1016/j.numecd.2012.02.007] [PMID: 22546554]
[41]
Miura K, Ohnishi H. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7381-91.
[http://dx.doi.org/10.3748/wjg.v20.i23.7381] [PMID: 24966608]
[42]
Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci 2016; 61(5): 1294-303.
[http://dx.doi.org/10.1007/s10620-016-4049-x] [PMID: 26841783]
[43]
Vespasiani-Gentilucci U, Carotti S, Perrone G, et al. Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD. Liver Int 2015; 35(2): 569-81.
[http://dx.doi.org/10.1111/liv.12531] [PMID: 24649857]
[44]
Gewecke KN-OS. Bacterial overgrowth: Nutrition as part of the therapeutic concept. Small Intestinal Bacterial Overgrowth (SIBO). Ernahr-Umsch 2017; 4(64): 67-73.
[45]
Rezaie A, Pimentel M, Rao SS. How to test and treat small intestinal bacterial overgrowth: An evidence-based approach. Curr Gastroenterol Rep 2016; 18(2): 8.
[http://dx.doi.org/10.1007/s11894-015-0482-9] [PMID: 26780631]
[46]
Quigley EMM. The spectrum of small intestinal bacterial overgrowth (SIBO). Curr Gastroenterol Rep 2019; 21(1): 3.
[http://dx.doi.org/10.1007/s11894-019-0671-z] [PMID: 30645678]
[47]
Chen B, Kim JJW, Zhang Y, Du L, Dai N. Prevalence and predictors of small intestinal bacterial overgrowth in irritable bowel syndrome: A systematic review and meta-analysis. J Gastroenterol 2018; 53(7): 807-18.
[http://dx.doi.org/10.1007/s00535-018-1476-9] [PMID: 29761234]
[48]
Shah A, Shanahan E, Macdonald GA, et al. Systematic review and meta-analysis: Prevalence of small intestinal bacterial overgrowth in chronic liver disease. Semin Liver Dis 2017; 37(4): 388-400.
[http://dx.doi.org/10.1055/s-0037-1608832] [PMID: 29272899]
[49]
Steed H, Macfarlane GT, Blackett KL, et al. Bacterial translocation in cirrhosis is not caused by an abnormal small bowel gut microbiota. FEMS Immunol Med Microbiol 2011; 63(3): 346-54.
[http://dx.doi.org/10.1111/j.1574-695X.2011.00857.x] [PMID: 22092561]
[50]
Volynets V, Küper MA, Strahl S, et al. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with Non-Alcoholic Fatty Liver Disease (NAFLD). Dig Dis Sci 2012; 57(7): 1932-41.
[http://dx.doi.org/10.1007/s10620-012-2112-9] [PMID: 22427130]
[51]
Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48(2): 206-11.
[http://dx.doi.org/10.1136/gut.48.2.206] [PMID: 11156641]
[52]
Sajjad A, Mottershead M, Syn WK, Jones R, Smith S, Nwokolo CU. Ciprofloxacin suppresses bacterial overgrowth, increases fasting insulin but does not correct low acylated ghrelin concentration in non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2005; 22(4): 291-9.
[http://dx.doi.org/10.1111/j.1365-2036.2005.02562.x] [PMID: 16097995]
[53]
Sabaté JM, Jouët P, Harnois F, et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: A contributor to severe hepatic steatosis. Obes Surg 2008; 18(4): 371-7.
[http://dx.doi.org/10.1007/s11695-007-9398-2] [PMID: 18286348]
[54]
Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49(6): 1877-87.
[http://dx.doi.org/10.1002/hep.22848] [PMID: 19291785]
[55]
Shanab AA, Scully P, Crosbie O, et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: Association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011; 56(5): 1524-34.
[http://dx.doi.org/10.1007/s10620-010-1447-3] [PMID: 21046243]
[56]
Fialho A, Fialho A, Thota P, McCullough AJ, Shen B. Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease. J Gastrointestin Liver Dis 2016; 25(2): 159-65.
[http://dx.doi.org/10.15403/jgld.2014.1121.252.iwg] [PMID: 27308646]
[57]
Ghoshal UC, Baba CS, Ghoshal U, et al. Low-grade small intestinal bacterial overgrowth is common in patients with non-alcoholic steatohepatitis on quantitative jejunal aspirate culture. Indian J Gastroenterol 2017; 36(5): 390-9.
[http://dx.doi.org/10.1007/s12664-017-0797-6] [PMID: 29034439]
[58]
Tkach S, Gubska O, Cheverda T. The efficacy of eradication of small intestinal bacterial overgrowth in patients with non-alcoholic fatty liver disease. EUREKA: Health Sciences 2017; (4): 34-41.
[http://dx.doi.org/10.21303/2504-5679.2017.00395]
[59]
Rafiei R, Bemanian M, Rafiei F, et al. Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth. Rom J Intern Med 2018; 56(2): 85-9.
[http://dx.doi.org/10.1515/rjim-2017-0042] [PMID: 29101772]
[60]
Martins IJ. Overnutrition determines LPS regulation of mycotoxin induced neurotoxicity in neurodegenerative diseases. Int J Mol Sci 2015; 16(12): 29554-73.
[http://dx.doi.org/10.3390/ijms161226190] [PMID: 26690419]
[61]
Martins IJ. Anti-aging genes improve appetite regulation and reverse cell senescence and apoptosis in global populations 2016; 5: 9- 26.
[http://dx.doi.org/10.4236/aar.2016.51002]
[62]
Jasirwan COM, Lesmana CRA, Hasan I, Sulaiman AS, Gani RA. The role of gut microbiota in non-alcoholic fatty liver disease: Pathways of mechanisms. Biosci Microbiota Food Health 2019; 38(3): 81-8.
[http://dx.doi.org/10.12938/bmfh.18-032] [PMID: 31384519]
[63]
Kapil S, Duseja A, Sharma BK, et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2016; 31(1): 213-21.
[http://dx.doi.org/10.1111/jgh.13058] [PMID: 26212089]
[64]
Li K, Lv G, Pan L. Sirt1 alleviates LPS induced inflammation of periodontal ligament fibroblasts via downregulation of TLR4. Int J Biol Macromol 2018; 119: 249-54.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.07.099] [PMID: 30026098]
[65]
Fu C, Hao S, Xu X, et al. Activation of SIRT1 ameliorates LPS-induced lung injury in mice via decreasing endothelial tight junction permeability. Acta Pharmacol Sin 2019; 40(5): 630-41.
[http://dx.doi.org/10.1038/s41401-018-0045-3] [PMID: 30022154]
[66]
Andrade JMO, Paraíso AF, de Oliveira MVM, et al. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition 2014; 30(7-8): 915-9.
[http://dx.doi.org/10.1016/j.nut.2013.11.016] [PMID: 24985011]
[67]
Martins IJ. The future of genomic medicine involves the maintenance of sirtuin 1 in global populations. Mol Biol 2017; 2: 00013.
[68]
Li Y, Wong K, Giles A, et al. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21. Gastroenterology 2014; 146(2): 539-49.e7.
[http://dx.doi.org/10.1053/j.gastro.2013.10.059] [PMID: 24184811]
[69]
Ierardi E, Losurdo G, Sorrentino C, et al. Macronutrient intakes in obese subjects with or without small intestinal bacterial overgrowth: An alimentary survey. Scand J Gastroenterol 2016; 51(3): 277-80.
[http://dx.doi.org/10.3109/00365521.2015.1086020] [PMID: 26375876]
[70]
Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Dig Dis Sci 2004; 49(1): 73-7.
[http://dx.doi.org/10.1023/B:DDAS.0000011605.43979.e1] [PMID: 14992438]
[71]
Adike A, DiBaise JK. Small intestinal bacterial overgrowth: Nutritional implications, diagnosis, and management. Gastroenterol Clin 2018; 47(1): 193-208.
[http://dx.doi.org/10.1016/j.gtc.2017.09.008] [PMID: 29413012]
[72]
de Roest RH, Dobbs BR, Chapman BA, et al. The low FODMAP diet improves gastrointestinal symptoms in patients with irritable bowel syndrome: A prospective study. Int J Clin Pract 2013; 67(9): 895-903.
[http://dx.doi.org/10.1111/ijcp.12128] [PMID: 23701141]
[73]
Singh AU. Dysbiosis, small intestinal bacterial overgrowth and biofilms in autism and chronic illness. AIMS Mol Sci 2018; 5(2): 160-5.
[http://dx.doi.org/10.3934/molsci.2018.2.160]
[74]
Ponziani FR, Gerardi V, Gasbarrini A. Diagnosis and treatment of small intestinal bacterial overgrowth. Expert Rev Gastroenterol Hepatol 2016; 10(2): 215-27.
[http://dx.doi.org/10.1586/17474124.2016.1110017] [PMID: 26636484]
[75]
Gibson GR, Hutkins R, Sanders ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol 2017; 14(8): 491-502.
[http://dx.doi.org/10.1038/nrgastro.2017.75] [PMID: 28611480]
[76]
Behrouz V, Aryaeian N, Zahedi MJ, Jazayeri S. Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial. J Food Sci 2020; 85(10): 3611-7.
[http://dx.doi.org/10.1111/1750-3841.15367] [PMID: 32885440]
[77]
Chong CYL, Orr D, Plank LD, Vatanen T, O’Sullivan JM, Murphy R. Randomised double-blind placebo-controlled trial of inulin with metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020; 12(4): 937.
[http://dx.doi.org/10.3390/nu12040937] [PMID: 32230987]
[78]
Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 2007; 50(11): 2374-83.
[http://dx.doi.org/10.1007/s00125-007-0791-0] [PMID: 17823788]
[79]
Stachowska E, Portincasa P, Jamioł-Milc D, Maciejewska-Markiewicz D, Skonieczna-Żydecka K. The relationship between prebiotic supplementation and anthropometric and biochemical parameters in patients with NAFLD-A systematic review and meta-analysis of randomized controlled trials. Nutrients 2020; 12(11): 3460.
[http://dx.doi.org/10.3390/nu12113460] [PMID: 33187278]
[80]
Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014; 11(8): 506-14.
[http://dx.doi.org/10.1038/nrgastro.2014.66] [PMID: 24912386]
[81]
Hu H, Lin A, Kong M, et al. Intestinal microbiome and NAFLD: Molecular insights and therapeutic perspectives. J Gastroenterol 2020; 55(2): 142-58.
[http://dx.doi.org/10.1007/s00535-019-01649-8] [PMID: 31845054]
[82]
Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr 2014; 99(3): 535-42.
[http://dx.doi.org/10.3945/ajcn.113.068890] [PMID: 24401715]
[83]
Perumpail BJ, Li AA, John N, et al. The therapeutic implications of the gut microbiome and probiotics in patients with NAFLD. Diseases 2019; 7(1): 27.
[http://dx.doi.org/10.3390/diseases7010027] [PMID: 30823570]
[84]
Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: Can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019; 50(6): 628-39.
[http://dx.doi.org/10.1111/apt.15416] [PMID: 31373710]
[85]
Karczewski J, Troost FJ, Konings I, et al. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol 2010; 298(6): G851-9.
[http://dx.doi.org/10.1152/ajpgi.00327.2009] [PMID: 20224007]
[86]
Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for preventing and treating small intestinal bacterial overgrowth: A meta-analysis and systematic review of current evidence. J Clin Gastroenterol 2017; 51(4): 300-11.
[http://dx.doi.org/10.1097/MCG.0000000000000814] [PMID: 28267052]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy